Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Intervenciones para la prevención y el tratamiento de la osteoporosis inducida por corticosteroides y la prevención de fracturas osteoporóticas en la distrofia muscular de Duchenne

Información

DOI:
https://doi.org/10.1002/14651858.CD010899.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 24 enero 2017see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Neuromuscular

Copyright:
  1. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Jennifer M Bell

    Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK

  • Michael D Shields

    Correspondencia a: Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK

    [email protected]

  • Janet Watters

    GP Out of Hours Service, Belfast Health and Social Care Trust, Belfast, UK

  • Alistair Hamilton

    Withers Orthopaedic Centre, Belfast Health and Social Care Trust, Belfast, UK

  • Timothy Beringer

    Department of Care for the Eldery, Belfast Health and Social Care Trust, Belfast, UK

  • Mark Elliott

    Musgrave Park Hospital, Belfast Health and Social Care Trust, Belfast, UK

  • Rosaline Quinlivan

    MRC Centre for Neuromuscular Diseases and Dubowitz Neuromuscular Centre, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery and Great Ormond Street, London, UK

  • Sandya Tirupathi

    Paediatric Neurology, Royal Belfast Hospital for Sick Children, Belfast, UK

  • Bronagh Blackwood

    Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK

Contributions of authors

Jennifer Bell prepared the protocol with discussion and comments from review authors. Dr Janet Watters reviewed the text from the perspective of a healthcare consumer as the mother of a boy with Duchenne muscular dystrophy.
Conceiving the review: MS; BB
Co‐ordinating the review: JMB
Undertaking manual searches: JMB
Organising retrieval of papers: JMB
Screening retrieved papers against inclusion criteria: JMB; MS
Writing to authors of papers for additional information: JMB
Data management for the review: JMB
Data extraction and quality assessment: JMB; MS
Interpretation of data: JMB; MS; BB
Writing the review: JMB with contributions from all authors
Guarantor for the review (one author): MS
Person responsible for reading and checking the review before submission: JMB and all authors

Sources of support

Internal sources

  • No sources of support supplied

External sources

  • Health Research Board/HSC R&D Division Cochrane Fellowship Award, Ireland.

Declarations of interest

JMB: none known
TB: acknowledges financial support received from Servier Laboratories Ltd and Amgen UK Ltd to attend national conferences and payment with respect to chairman and speakers fees.
BB: none known
ME: none known
AH: none known
RQ: is Joint Co‐ordinating Editor of Cochrane Neuromuscular and is the author of two consensus workshop reports for bone health in Duchenne muscular dystrophy. Dr Quinlivan has received an honorarium from Genzyme for lecturing on metabolic muscle disease, as well as consultancy fees from Novartis and Guidepoint Global.
MDS: has received honoraria from GlaxoSmithKline, AstraZeneca, Novartis, Merck Sharp & Dohme, and ALK‐Abelló for lectures given at educational meetings and received hospitality to attend the European Respiratory Society and British Thoracic Society annual meetings.
ST: none known
JW: a member of charities Action Duchenne and the Muscular Dystrophy UK.

Acknowledgements

We wish to thank Angela Gunn, Information Specialist, Cochrane Neuromuscular, for assistance with the development of the search strategy.

We thank Dr Ruth Brassington, Managing Editor, Cochrane Neuromuscular, for support and guidance during the writing process.

This review was supported by funding provided from the Cochrane Fellowship scheme, HSC R&D Division, Public Health Agency Northern Ireland.

This project was supported by the National Institute for Health Research via Cochrane Infrastructure funding to Cochrane Neuromuscular. The views and opinions expressed herein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health. Cochrane Neuromuscular is also supported by the MRC Centre for Neuromuscular Diseases.

Version history

Published

Title

Stage

Authors

Version

2017 Jan 24

Interventions to prevent and treat corticosteroid‐induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy

Review

Jennifer M Bell, Michael D Shields, Janet Watters, Alistair Hamilton, Timothy Beringer, Mark Elliott, Rosaline Quinlivan, Sandya Tirupathi, Bronagh Blackwood

https://doi.org/10.1002/14651858.CD010899.pub2

2014 Mar 19

Interventions to prevent steroid‐induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophy

Protocol

Jennifer M Bell, Bronagh Blackwood, Michael D Shields, Janet Watters, Alistair Hamilton, Timothy Beringer, Mark Elliott, Rosaline Quinlivan, Sandya Tirupathi

https://doi.org/10.1002/14651858.CD010899

Differences between protocol and review

Lack of data prevented full implementation of our protocol (Bell 2014).

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Adolescent; Child; Child, Preschool; Humans; Male;

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

A flow diagram illustrating the study selection process.
Figuras y tablas -
Figure 1

A flow diagram illustrating the study selection process.

Ir a la figura de la revisiónAbrir en una pestaña nueva

'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. Green = low risk of bias; yellow = unclear risk of bias; red (not shown) = high risk of bias.
Figuras y tablas -
Figure 2

'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. Green = low risk of bias; yellow = unclear risk of bias; red (not shown) = high risk of bias.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Table 1. Spine and whole‐body Z‐scores (McSweeney 2014)

Risedronate (plus calcium and vitamin D supplementation)

Control (calcium and vitamin D supplementation alone)

Baseline

12‐month

Baseline

12 months

Median spine Z‐score (range)

‐1.75 (‐1.2 to ‐3.5)

‐0.8 (‐1.7 to 0)

‐2.2 (‐4.1 to ‐1.2)

‐1.6 (‐8.4 to ‐0.8)

Median whole‐body Z‐score (range)

‐1.95 (‐0.5 to 2.7)*

1.3 (‐1.0 to 2.5)

‐1.2 (‐1.6 to 4.7)

‐0.8 (‐3.1 to 3)

A median of ‐1.95 is outside the range given, but we were unable to confirm correct figures with the study author.

Figuras y tablas -
Table 1. Spine and whole‐body Z‐scores (McSweeney 2014)
Ir a la tabla de la revisión